Offline smartphone AI fundus screening detects diabetic retinopathy, glaucoma, and macular degeneration in one capture, delivering high accuracy for low-resource eye care.
|Poll|October 17, 2022
Poll results: Will you use biosimilars in your ophthalmic practice?
Author(s)Sheryl Stevenson, OT Staff Reports
Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.
Advertisement
Ophthalmology Times® polled our audience with the following question from September 26, 2022 to October 10, 2022: Will you use biosimilars in your ophthalmic practice?
The poll appeared on
37 responses were recorded, in total. Of these:
23% responded, "Yes, I plan to use biosimilars in my practice."
14% responded, "No, I do not plan to use biosimilars in my practice."
.
Advertisement
Related to this article
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Sura-vec is a 1-time investigational gene therapy designed to deliver sustained treatment in wet AMD, diabetic retinopathy and other chronic retinal conditions.
The trial over-enrolled and finished approximately 4 months ahead of initial projections, with 52-week topline data now expected in the second half of 2027.
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Study finds ChatGPT-5 overpredicts success after macular hole surgery—beating specialists on paper but missing failures.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
The Wills Retina Report: Mapping gene therapy for wet AMD with Carl D. Regillo, MD, and Allen C. Ho, MD
3
OCT-980 receives FDA orphan drug designation for retinitis pigmentosa
4
First patient dosed in phase 3 NPI-001 trial for Usher syndrome RP
5